{"name":"Onward Therapeutics","slug":"onward-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IMids","genericName":"IMids","slug":"imids","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"IMids","genericName":"IMids","slug":"imids","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNQ0Ridm4zdV84VURoRVpQdWVYNkJNTnhvVlpPRGFjUmJlc1pzaDZIYURENHVBNER6OEV5SDk1V0Rta3hOTVV5LWtyTFZiRVlyaXVHTTg5Zm5uUVY3S19TbEpNY3o4Z2cyWS1ULVFNTzB5SmFtQnpUNG9xSGxEY2s4cEdsa3FJekpNOFZ0Y2h3eEg0SzBFS0hqQ2RUTDBkeENPU3kxc2tkMjM?oc=5","date":"2026-03-31","type":"trial","source":"HCPLive","summary":"ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD - HCPLive","headline":"ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaGRpZVdLSnBhOFNwZjFBajdudmowRUl4ME1hN0RQd0YxemJDamh0NHIzUmF6bC1BUWZadEN0QndqdVVTOGxfVnl4Yi1pby1rcy1Pb3NuSnlFZURHX1ZOM1F6c0VsZDR3alJHWUxlTUdYaFVYX1ZWck1nNHBhSUlBYXRIX1NaX1dxQWxwODBVZTdONjJxejI1U18wZUpFUXB4SnlwYVoxQ3NqVENzUjdmZTBScFZMQnZYTTRMNGN0RlM?oc=5","date":"2026-01-21","type":"deal","source":"Fierce Biotech","summary":"Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech - Fierce Biotech","headline":"Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1vZ2t2Mjk5alF3b3ZiZjM3U1ZySWJvNjNIdHg0dWw5SklleE5sSkY0emxHT3otMng3Zm1GakZjbW1ueGpkOWpwZjExZ2xZVzdZZi1N?oc=5","date":"2025-12-22","type":"pipeline","source":"FirstWord Pharma","summary":"Big pharma-backed Aktis lines up for IPO - FirstWord Pharma","headline":"Big pharma-backed Aktis lines up for IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPQTNkWHFwNlktX1pseXdKNDNXTVc2U1lzSnIyRHFxeFFQZTBnMHB0WUZFTGFfeG9BUDJVWTdReVY0c0FfTVhndGRwbDVxd3VtSkJoVER2RDVhdkpxU0l5RzV6NUVvS3lfT2tfQ2ltanM5UFFzS0pGQVRoOVgxYnJ3X3R1ZHAxX1dTRDV0eVJQRk42cDVBallZWktiZkZub1NsWkNlSkp2R2ZveDRIaVI1b2V0emFsalhjYUxJYW9yRDQwUzFVcER0UHNIOFBpMG9faU90TWhBR3ExdmlPdkVv?oc=5","date":"2025-11-10","type":"earnings","source":"PR Newswire","summary":"Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan - PR Newswire","headline":"Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxOVFIzUUxfb21qU0t2S1BmM2dQeHV6YjQwa1c4TmRnWXliUkhIN056cndKV2drYkhFNW1MYkpKRXd1ZkFZOHdVVjA4eW1ZTWZRWFZlLWRzeFJad3pBa2djVmpyTXpseGE2TFE2SDJHcFNnU2dQYjBEbkdpLXM4M01fUHQ4VmhWZElycjRFck1Sal9BeEV6Y2JGdVlFOEFMSE9ZZjc1TWd4c2haZTZZMldiU19rT20zYzdsUVlxU1dCeVBVSW1mZDdmSXJpMXlPVW1hWUVnYnFvWWFlTG82dlVoZlA1REZOZHc4dVg3YnBDUGtBSUc5VmlySFlGOGhwMzdPQW1GSmNzQXJ5ZTB1X1dIdF9vNzBVM0lFdl9uSmJOQy0yQ3Y1QV9WTG9WNzF2U0hHT01pV3VOcHE?oc=5","date":"2025-10-27","type":"deal","source":"PR Newswire","summary":"Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program - PR Newswire","headline":"Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpell","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOejV0OVV6VzE0TTM3VnJSOEZhNUVzNDhBbUtYclF4M0ZnamhWWU5aVThDSjVTblVwaWFFMTQ4LXlVOVpNSjhDT3g0LU85WmFlWnhUenJWaFlMcUxYaFdsbWVXMzRNNFkwWlhjVGlTd01nZGRFdnppb2xqOVRDSEpBVTQ0c3NDazM0VXZEbHFRZ0VxNkl3aXZMb2pjYzRnQQ?oc=5","date":"2025-10-27","type":"pipeline","source":"Greater Geneva Bern area","summary":"ONWARD Medical raises over EUR 50 million to advance spinal cord therapies - Greater Geneva Bern area","headline":"ONWARD Medical raises over EUR 50 million to advance spinal cord therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNdFNyUjFhUW9VNHlTSHVLSGdwQ1lRdm9zX1l4TklsZXhkV1JQUzRHM0JsdFlIb2dWdmV2dDBPQ2JVeHVwQmkxb0cyRzVsYmFhUkYyYy04WmpBVk1pdTlIMXNQSWtKLVFGSHR1U0doMzJiSXNaeDViT0w4Z1VJbXJEdEVXZ1ViTnRfSnhRUzdJNnRDdEZXeFluR1Q2dDctZnlfSERNd3VOazVmY21veUFHNkhn?oc=5","date":"2025-09-05","type":"pipeline","source":"Fierce Biotech","summary":"Led by ex-HI-Bio CEO, Braveheart pays $65M to challenge BMS for heart disease market - Fierce Biotech","headline":"Led by ex-HI-Bio CEO, Braveheart pays $65M to challenge BMS for heart disease market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE83RmZFVkhaNGVzbEpKaWxoRUVmUUhNWEVDXzBUamgyRVdkY1B6REc1eXRPSGozUnVRamthYlBHbkxGVDRZMTN1bGM3N0VpZUowSm8ycVZRTGQ5bmJ0OEFHM1JEcl9IZzByZlBTVzh0TmlxbXJLNFNJR1pJUzRLYjg?oc=5","date":"2025-07-09","type":"trial","source":"Oncology Pipeline","summary":"When two antigens are better than one | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"When two antigens are better than one | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPZmN3ZUNLbG5Jand2bUV5Mm9yczRndldDelR3bVdOeXNmbGN6VVliNURyZkFLYTdVUlJ4bDFWX3puWmZBWkFsNndZMXpPaER2Qm9yUXVqSW8zSHhuenNzS1JlbW5LOVBneVhrYkQzbm1heDdlaXJoNEtfeWNfU1VwSUNMbmlITHBfZzdOLTh4LXhTa01Cdmh0QmMzM0NpdklqZU4tUmE3MWQtc3lBT1NhSHN6THpUU2hSLWdkcUpvSmo4c05DczRWS01wNEhpZUtz?oc=5","date":"2025-05-08","type":"regulatory","source":"Psychiatric Times","summary":"FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times","headline":"FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLXlaVUVlbEJmTUVqb2I3UG54aFlKQnJiQ1dVNG9RVlJVMXZ3TFdBUFNjOVl3WGU3SGkwSGhveUxVS0tubnVXbGpWa0JPa196QzJObXNGNURVMlNfYURGcXpPWTFhajR5T0dkSkRVbHV0Tm5jMUtjb3dzMDk1TWtPNHMxTUplQUR6VzZWLWhYaFNfVzBLOGpKNTVB?oc=5","date":"2025-04-23","type":"pipeline","source":"startupticker.ch","summary":"Swiss biotechs on track to address key medical challenges - startupticker.ch","headline":"Swiss biotechs on track to address key medical challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE8tOGdGcnZxeFAwR3VFZFFaYUJnR0tQdVJDZ051bmdvaU1FaEc2Z3dkZWRGeEc0bW93dnhWSlptZkt0SENCVDE2cUJ5MHVaY1IyQzNWXzZtdmdNdWt3cXVZQkhXTmN0dHVfUGlzTmczSmtpcmVyc2hfNzJ3?oc=5","date":"2024-01-25","type":"trial","source":"Clinical Trials Arena","summary":"Onward Therapeutics begins Phase I cancer antibody trial - Clinical Trials Arena","headline":"Onward Therapeutics begins Phase I cancer antibody trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNZjBtX0RoZUlVRWN3SUtnWnFQaHRWU1Q0T0tLRFZUMU91RGlSbWtlODVPMUVRcXMtRzcyb3JPRmczbUVDSXRIbE96aElKcjV5MEVVeElkWWhKRzJ1eUxqYS02cUpUUkd6eXdlVFE1QUVvdzNiNjhqcUIydUlHX1JtSmNlVHBtZjFNYTZNYUk3QkMxUDZHWk5zMXFob2gwSE5tTzhQajlVUjlpSk5WTE1WaFJyU0dXbEYxTUJDZTZac2dIYXYtZGFhRTdLZ0pTRTJ2V1lmS3VjSmRoTHdITGUzMkc5Z1l2VWxMZXhmRG9COFRZX1l1QVdKMElGSTJJODNhZVJ0clVIZGZrMDVaUEZDUHduS2VEWXM?oc=5","date":"2021-02-16","type":"deal","source":"BioSpace","summary":"Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology - BioSpace","headline":"Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement t","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}